Kemin Pharma opens office in India

Belgium-based Kemin Pharma, a division of Kemin Industries South Asia Private, has announced the opening of its new offices in Chennai, India. The facility will enable Kemin to expand its R&D activities in India, as the organization advances its pipeline of human therapeutic products through clinical development and the launch of its lead product, the Bacillus subtilis probiotic PB6 into global markets. The office will initially have a staff up to 20, with research facilities at the same location as well as in Gummidpundi.

"We have been operating in India over the past year primarily in early clinical research," said Kemin's president, Keith Bostian. "We are now well poised to increase our team and capabilities in India as an integral component of our global R&D effort. Our plans in India are to move toward earlier preclinical development and discovery stages of the pharmaceutical research process, aiming to become a lead company in the rapidly growing Indian pharmaceutical industry," he added.